FDA warns of increased heart-related issues from Pfizer's arthritis drug Xeljanz

In this article:

Dec 3 (Reuters) - The U.S. Food and Drug Administration added a new black-box warning, its harshest, to the label of Pfizer Inc's arthritis drug, Xeljanz, citing increased risk of major cardiac-related problems in some patients, the drugmaker said on Friday. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva)

Advertisement